Consequently, BP management is a central focus of CKD care guidelines, with recommendations tailored to disease stage and comorbidities. According to the most recent Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, the comprehensive management of CKD involves three therapeutic pillars: BP control, renin-angiotensin-aldosterone system (RAAS) inhibition using angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), and reduction of proteinuria. This evidence concerns the gene REN and chronic kidney disease.